Neurohormonal and circulatory effects of short-term treatment with enalapril and quinapril in dogs with asymptomatic mitral regurgitation

Journal of Veterinary Internal Medicine

Volumn 19, Issue 5, 2005, Pages 712-719

  Moesgaard, Sophia Gry ^a   Pedersen, Lotte Gam ^a   Teerlink, Tom ^b   Häggström, Jens ^c   Pedersen, Henrik Duelund ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Angiotensin converting enzyme inhibitors; Asymmetric dimethylarginine; Echocardiography; Mitral valve prolapse; Nitrate and nitrite

Indexed keywords

ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; ENALAPRIL; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; NATRIURETIC FACTOR; NITRIC OXIDE; QUINAPRIL; RENIN; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; ENZYMOLOGY; FEMALE; MALE; MITRAL VALVE REGURGITATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARGININE; CROSS-OVER STUDIES; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENALAPRIL; FEMALE; MALE; MITRAL VALVE INSUFFICIENCY; NATRIURETIC AGENTS; NITRIC OXIDE; RENIN; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 26844441982     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19[712:NACEOS]2.0.CO;2     Document Type: Article

References (61)

1. Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 1965;127:481-516.
2. Devereux RB. Recent developments in the diagnosis and management of mitral valve prolapse. Curr Opin Cardiol 1995;10:107-116.
3. Pedersen HD, Häggström J. Mitral valve prolapse in the dog: A model of mitral valve prolapse in man. Cardiovasc Res 2000;47:234-243.
4. Pedersen HD, Lorentzen KA, Kristensen BØ. Echocardiographic mitral valve prolapse in Cavalier King Charles Spaniels: Epidemiology and prognostic significance for regurgitation. Vet Rec 1999;144:315-320.
5. Pedersen HD, Schütt T, Søndergaard R, et al. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003;17:178-184.
6. Katz SD. The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Prog Cardiovasc Dis 1995;38:23-50.
7. Chen J, Hsu N, Wu T, et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-982.
8. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation 1998;98:2652-2656.
9. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-1596.
10. Bernstein RD, Zhang X, Zhao G, et al. Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs. Nitric Oxide 1997;1:386-396.
11. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: A critical evaluation. Clin Chem 1995;41:892-896.
12. Zeballos GA, Bernstein RD, Thompson CI, et al. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation 1995;91:2982-2988.
13. Osorio JC, Xu X, Vogel T, et al. Plasma nitrate accumulation during the development of pacing-induced dilated cardiac myopathy in conscious dogs is due to renal impairment. Nitric Oxide 2001;5:7-17.
14. Böger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
15. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-548.
16. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Cardiovasc Res 1999;43:542-548.
17. Takiuchi S, Fujii H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004;17:802-808.
18. Huang LF, Guo FQ, Liang YZ, Li BY, Cheng BM. Simultaneous determination of L-arginine and its mono- and dimethylated metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 2004;380:643-649.
19. Studer R, Reinecke H, Müller B, et al. Increased angiotensin-I converting enzyme gene expression in the failing human heart. J Clin Invest 1994;94:301-310.
20. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-2848.
21. O'Kane KPJ, Webb DJ, Collier JG, Vallance PJT. Local L-N-mono-methyl- arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 1994;38:311-315.
22. Mombouli JV, Illiano S, Nagao T, et al. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin-I converting enzyme inhibitors in canine coronary arteries involve both endothelium-derived relaxing factor and hyperpolarizing factors. Circ Res 1992;71:137-144.
23. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study). J Am Coll Cardiol 2000;35:60-66.
24. Kvart C, Häggström J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
25. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5.
26. Lyons D, Webster J, Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-378.
27. Kaplan HR, Taylor DG, Olson SC. Quinapril: Overview of preclinical data. Clin Cardiol 1990;13:VII-6-12.
28. Rasmussen F, Hoff-Jørgensen R, Nielsen P, et al, eds. Veterinary Drug Catalogue of the Danish Veterinary Association, 1st ed. Copenhagen, Denmark: VIF; 2005:210-211.
29. Nielsen AH, Schauser KH, Svenstrup B, Poulsen K. Angiotensin converting enzyme in bovine ovarian follicular fluid and its relationship with oestradiol and progesterone. Reprod Domest Anim 2002;37:81-85.
30. Poulsen K, Jørgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocr Metab 1974;39:816-825.
31. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PAM. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002;303:131-137.
32. DiBianco R. ACE inhibitors in the treatment of heart failure. Clin Cardiol 1990;13:VII-32-38.
33. Morisse B, Kersten U. Die Behandlung der Herzinsuffizienz des hundes mit ACE-hemmern: Quinapril und Captopril im vergleich. Tierärztl Prax 1995;23:489-496.
34. Martinez-Alcaine MA, Ynaraja E, Corbera JA, Montoya JA. Effect of short-term treatment with bumetanide, quinapril and low-sodium diet on dogs with moderate congestive heart failure. Aust Vet J 2001;79:102-105.
35. Olson SC, Horvath AM, Michniewicz BM, et al. The clinical pharmacokinetics of quinapril. Angiology 1989;40:360-369.
36. Schwartz JB, Taylor A, Abernethy DJ, et al. Pharmacokinetics and pharmacodynamics of enalpril in patients with congestive heart failure and patients with hypertension. Cardiovasc Pharmacol 1985;7:767-776.
37. Chen HH, Lainchbury JG, Matsuda Y, et al. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 2001;38:187-191.
38. Fitzpatrick D, Nicholls MG, Ikram H, Espiner EA. Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J 1983;50:163-169.
39. Levine TB, Olivari MT, Garberg V, et al. Hemodynamic and clinical response to enalapril, a long acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation 1984;69:548-553.
40. Koch J, Pedersen HD, Jensen AL, et al. Short term effects of acute inhibition of the angiotensin-converting enzyme on the renin-angiotensin system and plasma atrial natriuretic peptide in healthy dogs fed a low-sodium diet versus a normal-sodium diet. Zentralbl Veterinärmed A 1994;41:121-127.
41. Häggström J, Hansson K, Karlberg BE, et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin- aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996;57:1645-1652.
42. Häggström J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin- aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997;58:77-82.
43. Häggström J, Hansson K, Kvart C, et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol 2000;2:7-16.
44. Schmitt M, Gunaruwan P, Payne N, et al. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol 2004;24:911-917.
45. Wennberg PW, Miller VM, Rabelink T, Burnett JC Jr. Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol 1999;277:H1618-H1621.
46. Häggström J, Hansson K, Karlberg BE, et al. Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. Am J Vet Res 1994;55:698-703.
47. Ohnishi M, Wada A, Tsutamoto T, et al. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci 2002;103(Suppl 48):241S-244S.
48. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 2004; 134(10 Suppl):2842S-2847S.
49. Camsari A, Pekdemir H, Cicek D, et al. Endothelin-1 and nitric oxide levels in patients with mitral annulus calcification. Jpn Heart J 2004;45:487-495.
50. Nickenig G, Stäblein A, Wassman S, et al. Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000;1:361-364.
51. Yavuz D, Koc M, Toprak A, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003;4:197-203.
52. Kon-Koh K, Bui MN, Hathaway L, et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 1999;83:327-331.
53. de Laforcade AM, Freeman JE, Rush JE. Serum nitrate and nitrite in dogs with spontaneous cardiac disease. J Vet Intern Med 2003;17:315-318.
54. Moriguchi T, Shimomitsu T, Odagiri Y, et al. Circadian changes in urinary bicarbonate, nitric oxide metabolites and pH in female player during handball camp involved in an exercise, rest and sleep cycle. Tohoku J Exp Med 2002;196:281-291.
55. Maeda S, Miyauchi T, Iemitsu M, et al. Endothelin receptor antagonist reverses decreased NO system in the kidney in vivo during exercise. Am J Physiol Endocrinol Metab 2004;286:E609-E614.
56. Green DJ, Bilsborough W, Naylor LH, et al. Incremental handgrip and cycle ergometer exercise: Relative contribution of nitric oxide. J Physiol 2005;562:617-628.
57. Zdrenghea D, Bodizs G, Ober MC, Ilea M. Ischemic preconditioning by repeated exercise tests involves nitric oxide up-regulation. Rom J Intern Med 2003;41:137-144.
58. Cetnarowski-Cropp AB. Quinapril: A new second-generation ACE inhibitor. DICP Ann Pharmacother 1991;25:499-504.
59. Johnston CI, Jandeleit K, Mooser V, et al. Angiotensin-converting enzyme and its inhibition in the heart and blood vessels. J Cardiovasc Pharmacol 1992;20:S6-S11.
60. Brown SA, Finco DR, Brown CA, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res 2003;64:321-327.
61. Hamlin RL, Benitz AM, Ericsson GF, et al. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. J Vet Intern Med 1996;10:85-87.